Cara Therapeutics, Inc. has completed enrollment in its Phase 2 proof-of-concept trial of its lead kappa opioid agonist, CR845, for the treatment of uremic pruritus.

“We look forward to announcing top-line data,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of the company. “This is an area of high unmet need for dialysis patients and we believe that I.V. CR845 has the potential to significantly reduce their itch burden and improve overall quality of life.”